Newsroom | 5423 results

MALVERN, Pa.--(BUSINESS WIRE)--NexEos Bio Vision Health (“NexEos”), a clinical-stage biopharmaceutical company developing novel therapies and diagnostics targeting eosinophil-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared NexEos’s Investigational New Drug (IND) Application to proceed to a Phase II/III clinical trial of NTX-1024 for the treatment of patients with the rare disease, vernal keratoconjunctivitis (VKC). The planned Phase II/III trial i...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome announces the publication of positive preclinical results in uveitis, addressing a $3B potential market opportunity...

DULUTH, Ga.--(BUSINESS WIRE)--National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision” or the “Company”) will report its fourth quarter and fiscal 2025 financial results before the market opens on Wednesday, March 4, 2026, and will host a conference call at 8:30 a.m. Eastern Time. To pre-register for the conference call and obtain a dial-in number and passcode, please refer to the “Investors” section of the Company’s website at https://ir.nationalvision.com. A live audio webcast of the c...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its fourth-quarter and full-year 2025 financial results. “We didn’t just grow in the fourth quarter – we grew smarter,” said Brent Saunders, chairman and CEO, Bausch + Lomb. “Meaningful EBITDA margin expansion and operating leverage is a clear sign of our commitment to financial excellence, and we plan to harnes...

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the strategic expansion of its Regulatory Affairs & Quality department with two senior appointments following recent regulatory milestones. The company named...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2025. Key highlights include: Record net sales of $143.1 million in Q4 2025 increased 36% year-over-year on a reported basis and 34% year-over-year on a constant currency basis....

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded age indication for EVO/EVO+ Visian® Implantable Collamer Lenses, extending use to patients 21 to 60 years old. The approval came shortly after publication of three-year FDA clinical trial safety data, reinforcing...

GENEVA--(BUSINESS WIRE)--Alcon Launches TOTAL30 Multifocal for Astigmatism, the World’s Only Monthly Multifocal Toric Contact Lens with Water Gradient Technology...

SAN DIEGO--(BUSINESS WIRE)--RevolutionEHR launches a modern, compliance-first patient portal that streamlines scheduling, billing, messaging, and records for optometry practices....

NEW YORK--(BUSINESS WIRE)--Warby Parker Inc. (NYSE: WRBY) (the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today announced that its financial results for the fourth quarter and year ended December 31, 2025 will be released before market open on February 26, 2026. In addition, the Company will discuss its results and business outlook during a live conference call and webcast at 8:00 a.m. Eastern Time. The conference call can be accessed by dialing 833-470-1428 fro...